Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Immatics (IMTX) reported a quarterly loss of $0.49 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.50, but worse than a loss of $0.12 per share a year ago, indicating an earnings surprise of +2.00% [1] - The company generated revenues of $6.06 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 50.71% and down from $55.57 million in the same quarter last year [2] - Immatics shares have increased approximately 43.5% year-to-date, outperforming the S&P 500's gain of 14.5% [3] Earnings Outlook - The future performance of Immatics' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.51 on revenues of $12.3 million, and for the current fiscal year, it is -$1.80 on revenues of $42.01 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Immatics belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, CureVac N.V. (CVAC), is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year decline of -110.3%, with revenues anticipated to be $14.52 million, down 97.3% from the previous year [9]